星标 ★ IPO日报 精彩文章第一时间推送 1月30日，中国证监会对《〈上市公司证券发行注册管理办法〉第九条、第十条、第十一条、第十三条、第四十条、第五十七条、第六十条有关规定的适 用意见——证券期货法律适用意见第18号》做了修改。 张力制图 一是扩大战略投资者类型。明确全国社保基金、基本养老保险基金、企业（职业）年金基金、商业保险资金（保险公司运用保险资金自行投资或者委托关 联保险资产管理机构以及作为单一投资人通过关联保险资产管理机构发行的股权投资计划投资）、公募基金、银行理财等机构投资者可以作为战略投资 者，以耐心资本作为战略性资源对上市公司战略投资。同时，在规则上将该类投资者界定为资本投资者，将其他实业投资者界定为产业投资者。 二是明确最低持股比例要求。坚持战略投资者应当持有上市公司较大比例股份，进一步明确战略投资者本次认购上市公司股份原则上不低于 5%，可以根 据持股比例参与上市公司治理。 三是明确资本投资者的基本要求。在长期、较大比例持股和提名董事参与公司治理基础上，要求资本投资者应当深入了解上市公司产业发展，能够帮助上 市公司引入战略性资源，或者显著改善上市公司治理和内部控制，促进上市公司市场资源 ...

Core Viewpoint - Zhejiang Rongtai Electric Equipment Co., Ltd. is experiencing significant growth, with a market capitalization increase of over 9 times since its A-share listing, driven by its expansion into the robotics sector and strong performance in the new energy materials market [1][5][6]. Group 1: Company Overview - Zhejiang Rongtai, established in 1998, is a leading supplier of high-performance mica composite materials and has expanded its business into key precision components for robotics [4][6]. - The company ranks first globally in the mica products market for new energy applications, holding a market share of 22.6%, and also leads in the Chinese market with a 14.1% share [4][6]. Group 2: Financial Performance - From 2020 to 2022, Zhejiang Rongtai's revenue grew from 3.65 billion to 6.67 billion, with net profits increasing from 32.6 million to 134 million [7]. - In 2023, the company achieved revenue of over 800 million, with a projected growth of 41.8% to 1.135 billion in 2024, resulting in a compound annual growth rate of approximately 32.8% from 2020 to 2024 [7]. - The net profit for 2023 and 2024 is expected to be 172 million and 230 million respectively, reflecting growth rates of 28.43% and 34.02% [7]. Group 3: Strategic Investments and Future Plans - In 2025, Zhejiang Rongtai identified the potential in the humanoid robotics market and made strategic investments, including acquiring a 51% stake in Diz Precision and a 15% stake in Jinli Transmission [8]. - The company plans to use funds from its upcoming IPO to expand global production capacity, invest in strategic acquisitions, and enhance its research and development capabilities in both the robotics and new energy sectors [9][10].

星标 ★ IPO日报 精彩文章第一时间推送 近日，上海君屹工业自动化股份有限公司（下称"上海君屹"）首次向港交所递表，申请主板上市，国泰海通为其独家保荐人。 IPO日报注意到，上海君屹近年来营业收入和净利润增速亮眼，毛利率持续增长，2025年12月估值13.34亿元，但境外收入占比大幅下滑。 张力制图 净利润同比增长88.3% 报告期内，上海君屹毛利率为17.08%、18.83%、19.14%，持续增长。 境外收入缩水 资料显示，上海君屹的历史可追溯至2009年9月，由马翌鑫及前业务伙伴成立，是一家机器人自动化系统及解决方案集成商，公司为汽车产业提供定制化 汽车焊接自动化生产线解决方案，并为全球领先的汽车及电池制造商提供新能源电池模组与PACK自动化生产线解决方案。 上海君屹此前曾于2015年7月在新三板挂牌，后在2017年8月主动摘牌。公司曾于2021年及2022年谋划申请A股上市，但均未递交上市申请。此次，上海君 屹终于迈出了上市这一步。 招股书显示，上海君屹的业务主要包括两大部分，一是新能源汽车电池模组与PACK自动化生产线解决方案，即为动力电池制造商与储能电池制造商提供 电池模组与电池包组装的自动化生 ...

Core Viewpoint - 康诺生物制药股份有限公司 is preparing for an IPO on the Hong Kong Stock Exchange, with significant revenue fluctuations and a focus on mitochondrial medicine and health products [1][2][5]. Group 1: Company Overview - 康诺生物, established in 2017, specializes in the research and commercialization of drugs related to mitochondrial dysfunction, targeting cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [5]. - The market for mitochondrial medicine products in China is projected to grow from 95 billion yuan in 2020 to 179 billion yuan by 2024, with a compound annual growth rate (CAGR) of 17.1%, and expected to reach 308.1 billion yuan by 2035, with a CAGR of 29.5% from 2024 to 2035 [5]. Group 2: Financial Performance - 康诺生物's revenue for 2023 and 2024 was 3.03 billion yuan and 2.4 billion yuan, respectively, representing a decline of approximately 20.8%, while net profit dropped by 57.4% to 795.2 million yuan and 339.05 million yuan [6]. - In the first three quarters of 2025, the company reported a revenue of 238 million yuan, a year-on-year increase of 33%, and a net profit of 53.41 million yuan, up 93% [7]. Group 3: Product Portfolio - The flagship product, 恩艾地 (NAD⁺ injection), accounted for 65.2% of total revenue in the first three quarters of 2025, with revenues of 134 million yuan, 106 million yuan, and 155 million yuan in 2023, 2024, and 2025 respectively [9]. - The company has a total of 20 commercialized drugs, with 15 included in the national medical insurance directory, but 恩艾地 is not among them, which could impact future revenues if it is included [10]. Group 4: Future Prospects and R&D - 康诺生物 plans to use IPO proceeds to fund the development of several candidate drugs, including those targeting acute myocardial infarction and chronic heart failure, with clinical trials expected to complete by Q1 2027 [11]. - The company also aims to invest in the construction of smart biological factories and upgrade its sales and distribution networks, as well as digital infrastructure [11].

Core Viewpoint - The article discusses the IPO application of Kunshan Hongshida Intelligent Technology Co., Ltd., highlighting its reliance on the Apple supply chain for revenue and the associated risks [1][6]. Group 1: Company Overview - Hongshida specializes in the research, production, and sales of intelligent automation equipment and flexible production lines, targeting sectors such as consumer electronics, new energy, and semiconductors [3]. - The company reported revenues of 397 million yuan, 476 million yuan, and 649 million yuan for the years 2022, 2023, and 2024, respectively, with net profits of 29.69 million yuan, 38.53 million yuan, and 53.49 million yuan, indicating a consistent growth trend [3]. Group 2: Customer Dependency - The company has a high customer concentration, with sales to its top five customers accounting for 70.35%, 50.26%, and 62.67% of total revenue in 2022, 2023, and 2024, respectively [5]. - A significant portion of the company's revenue comes from the Apple supply chain, with income from this sector representing 77.34%, 62.37%, and 76.64% of its main business revenue during the same periods [7]. Group 3: Major Clients and Shareholding - Among its major clients, Pengding Holdings not only ranks as a top customer but also holds a 2.11% stake in Hongshida, raising questions about potential conflicts of interest [9]. - Sales to Pengding Holdings increased significantly after its investment, with revenues of 16.19 million yuan, 38.03 million yuan, and 101.03 million yuan reported for the years 2022, 2023, and 2024, respectively [10]. Group 4: Fundraising and Financial Strategy - The company plans to raise 216.95 million yuan, allocating funds for expanding manufacturing capacity, building a research center, repaying bank loans, and supplementing working capital [13]. - Nearly half of the raised funds will be used for repaying bank loans and enhancing liquidity, despite the company having 1.12 billion yuan in cash at the end of the reporting periods [14].

Core Viewpoint - WoKe FeiFan Technology Co., Ltd. is applying for an IPO on the Hong Kong Stock Exchange, with a focus on the Indonesian market as the largest Chinese cross-border 3C accessories company in the region, having raised approximately 257 million yuan and showing continuous growth in performance [1][10]. Group 1: Company Overview - WoKe FeiFan is a cross-border new retail enterprise with full-chain digital capabilities, primarily focused on Southeast Asia, particularly Indonesia, and also covering markets like Vietnam, Thailand, and the Philippines [4]. - The company provides high-cost performance products to small and medium-sized retail enterprises (SMEs) and end consumers in these regions [4]. - WoKe FeiFan has developed a series of well-known proprietary brands, including "VIVAN," "ROBOT," and "SAMONO," focusing on 3C accessories and small home appliances [6]. Group 2: Market Potential - The Southeast Asian retail market is experiencing structural growth, expanding from $693.4 billion in 2020 to an expected $879.9 billion by 2024, with a compound annual growth rate (CAGR) of approximately 6.3% from 2024 to 2029 [4]. - Indonesia's retail market is particularly strong, with the 3C accessories market projected to grow at a CAGR of 8.3% from 2024 to 2029 [5]. - Despite rapid growth, traditional retail still dominates in Indonesia, Vietnam, and the Philippines, accounting for 58.5%, 46.6%, and 55.4% of the market, respectively, indicating a significant demand for integrated digital transformation solutions [5]. Group 3: Financial Performance - For the first nine months of 2023, 2024, and 2025, WoKe FeiFan's revenues were approximately 908 million yuan, 1.049 billion yuan, and 880 million yuan, respectively, with a year-on-year growth of 15.5% expected in 2024 [9]. - Net profits for the same periods were approximately 18.32 million yuan, 20.35 million yuan, and 41.65 million yuan, with a year-on-year growth of about 11.1% in 2024 [9]. - The gross profit margins have shown a consistent increase, recorded at 33.6%, 35.6%, and 36.9% during the reporting period [9]. Group 4: IPO Use of Proceeds - The funds raised from the IPO will be used to enhance supply chain warehousing and logistics networks, expand marketing and channel networks, improve brand influence, upgrade digital capabilities, establish localized teams, and for general operational funds [9].

星标 ★ IPO日报 精彩文章第一时间推送 日前，杭州云动智能汽车技术股份有限公司(下称"云动智能")向港交所递交招股书，拟在主板上市，中金公司为其独家保荐人。 IPO日报注意到，云动智能九成营收来自第一大客户奇瑞汽车，但并未股权"绑定"奇瑞汽车。 张力制图 营收增长 招股书显示，云动智能成立于2016年，作为中国车载智能网联解决方案行业的国产供货商，为整车厂提供车载通信与智能网联整体解决方案，主要产品包 括车载联网控制单元（T-Box）、紧急呼叫终端（e Call）、中央网关以及部分传感与域控相关产品，并辅以定制化设计与技术服务。 根据咨询机构弗若斯特沙利文报告，云动智能是中国第三大国产车载通信解决方案供货商，市场份额7%，于2024年按4G车载联网控制单元出货量计，云 动智能的4G车载通信解决方案在所有国产供货商中位居市场首位，市场份额7.8%。紧急呼叫终端方面来看，按照2024年的紧急呼叫终端出货量计，云动 智能是第三大国产供货商，市场份额1%；按照2025年前九个月按紧急呼叫出货量计，云动智能在所有国产供货商中排名第二，前进一名，市场份额 1.4%。 2025年前九个月，云动智能5G车载通信解决方案出 ...

星标 ★ IPO日报 精彩文章第一时间推送 1月28日，北交所上市委计划召开审议会议，对浙江恒道科技股份有限公司（下称"恒道科技"）的IPO申请进行审核。 大约两年前，公司曾剑指创业板。然而，经历市场环境更迭和战略调整，恒道科技选择转战北交所。本次IPO，公司计划募集资金4.03亿元。 张力制图 比亚迪供应商 近年来，公司先后被浙江省经济和信息化厅评为"浙江省拟重点支持的'专精特新'中小企业"和"浙江省'隐形冠军'企业"，公司研发中心被认定为"浙江省省级企业研究开发中心"。截至招股说明书签署日，公司已经形成了12项发明专利、 24项实用新型专利、8项软件著作权，持续积极参与行业内的标准起草和修订工作，先后参与制定1项国家标准、3项团体标准。 经过多年市场耕耘与考验，恒道科技积累了丰厚的客户资源，先后成为国内外知名的汽车主机厂、汽车零部件厂和注塑模具厂的配套供应商。公司与比亚迪(002594.SZ)、安瑞光电(三安光电(600703.SH)之全资子公司)、嘉利股份 (874616.NQ)、星宇股份(601799.SH)、海泰科(301022.SZ)、格力电器(000651.SZ)等知名企业建立了长期稳定的合作关 ...

张力制图 这是网络流传陈小群种种传言之后，陈小群首次出场操作。从效果来看，市场在第一天还是认可他的市场地位，其席位溢价依然在。不过，1月 27日通宇通讯的股价走势来看，陈小群席位溢价的效果在打折。不知道是否巧合，与此同时，"陈XQ被抓了！"的传闻突然在投资圈悄然传开。 陈小群，这个名字在A股市场颇具传奇色彩。作为"90后"新生代游资代表，他曾在多只热门股票上创造过令人咋舌的收益记录，其操作手法被不 少散户奉为圭臬，各种社交媒体上充斥着对其"操盘技巧"的分析与追捧。 星标 ★ IPO日报 精彩文章第一时间推送 1月27日，通宇通讯的股价以52.7元收盘，下跌4.62%。 这是一只典型的"陈小群概念股"：1月23日，通宇通讯（002792）的龙虎榜显示，中国银河证券股份有限公司大连黄河路证券营业部（陈小群常 用席位）买入金额2.11亿元，占当日总成交额比例达6.47%，通宇通讯股价也强势涨停。 1月26日，通宇通讯以54.86元开盘，然后迅速上冲拉板，最高价57.35元，收盘价55.25元，上涨5.9%。 1月27日，通宇通讯开盘50.50元，盘中一度翻红至55.54元，最后以52.7元的价格收盘。 此前不久，证 ...

星标 ★ IPO日报 精彩文章第一时间推送 日前，南华生物医药股份有限公司（000504.SZ，*ST生物）发布公告，正式终止筹划近半年的重大资产重组事项。 公司原计划收购湖南慧泽生物医药科技有限公司（简称"慧泽生物医药"）51%的股权，以期拓展生物医药板块，但最终因交易各方未能就交易方案达成一 致而宣告终止。 2025年上半年，公司营收仍同比下滑8.40%，在此背景下，收购金弘新材成为其打破僵局、寻求生路的重要战略落子。 2025年8月12日，*ST生物披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公告》，宣布拟收购程泽能、易木林、长沙君合致远企业管 理咨询合伙企业（有限合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的慧泽生物医药51%股权。 张力制图 业绩困境 *ST生物的前身是1992年上市的港澳实业，经历多次易主与更名，于2015年定名"南华生物"进军生物医疗领域。 公司长期主营"生物医药"（干细胞、免疫细胞储存）和"节能环保"双主业。但其业绩始终起伏不定，核心的干细胞治疗研究产业化缓慢，收入仍依赖细胞 储存业务。 回溯过去，公司已多次在"ST"和"摘帽"间徘徊：因2014年至 ...